Lung transplantation is an option for patients who have respiratory insufficiency or failure and who remain at risk of death despite optimal medical treatment. The most common indications are COPD, idiopathic pulmonary fibrosis, cystic fibrosis, α1-antitrypsin deficiency, and primary pulmonary hypertension. Less common indications include interstitial lung disorders (eg, sarcoidosis), bronchiectasis, and congenital heart disease. Single and double lung procedures are equally appropriate for most lung disorders without cardiac involvement; the exception is chronic diffuse infection (eg, bronchiectasis), for which double lung transplantation is best. Heart-lung transplantation is indicated for Eisenmenger syndrome and for any lung disorder with severe ventricular dysfunction likely to be irreversible; cor pulmonale is not an indication because it often reverses after lung transplantation. Single and double lung procedures are about equally common and are at least 8 times more common than heart-lung transplantation.
Relative contraindications include age (single-lung recipients must be < 65; double-lung recipients, < 60; and heart-lung recipients, < 55), current cigarette smoking, previous thoracic surgery, and, for some cystic fibrosis patients and at some medical centers, lung infection with resistant strains of Burkholderia cepacia, which greatly increases mortality risk.
Nearly all donated lungs are from brain-dead (deceased), heart-beating donors. Grafts from non–heart-beating donors, called donation-after-cardiac-death (DCD) donors, are being increasingly used because lungs from more suitable donors are lacking. Rarely, living adult (usually parent-to-child) lobar transplantation is done when deceased-donor organs are unavailable. Donors must be < 65 and never-smokers and have no active lung disorder as evidenced by
Donor and recipients must be size-matched anatomically (by chest x-ray), physiologically (by total lung capacity), or both.
Timing of referral for transplantation should be determined by factors such as
The donor is anticoagulated, and a cold crystalloid preservation solution containing prostaglandins is flushed through the pulmonary arteries into the lungs. Donor organs are cooled with iced saline slush in situ or via cardiopulmonary bypass, then removed. Prophylactic antibiotics are often given.
Single lung transplantation requires posterolateral thoracotomy. The native lung is removed, and the bronchus, pulmonary artery, and pulmonary veins of the donor lung are anastomosed to their respective cuffs. The bronchial anastomosis requires intussusception or wrapping with omentum or pericardium to facilitate adequate healing. Advantages of single lung transplantation include a simpler operation, avoidance of cardiopulmonary bypass and systemic anticoagulation (usually), more flexibility concerning size matching, and availability of the contralateral lung from the same donor for another recipient. Disadvantages include the possibility of ventilation/perfusion mismatch between the native and transplant lungs and the possibility of poor healing of the single bronchial anastomosis.
Double lung transplantation requires sternotomy or anterior transverse thoracotomy; the procedure is similar to 2 sequential single transplants. The primary advantage is definitive removal of all diseased lung tissue in the recipient. The disadvantage is poor healing of the tracheal anastomosis.
Heart-lung transplantation requires median sternotomy with cardiopulmonary bypass. Aortic, right atrial, and tracheal anastomoses are required; the trachea is anastomosed immediately above the bifurcation. The primary advantages are improved graft function and more dependable healing of the tracheal anastomosis because of coronary-bronchial collaterals within the heart-lung block. Disadvantages include long operative time with the need for cardiopulmonary bypass, the need for close size matching, and use of 3 donor organs by one recipient.
Methylprednisolone IV is often given to recipients before reperfusion of the transplanted lung. A common immunosuppressive regimen combines a calcineurin inhibitor (cyclosporine or tacrolimus), a purine metabolism inhibitor (azathioprine or mycophenolate mofetil), and methylprednisolone or another corticosteroid. Prophylactic antithymocyte globulin (ATG) or OKT3 may also be given during the first 2 wk after transplantation. Corticosteroids may be omitted to facilitate healing of the bronchial anastomosis; higher doses of other drugs (eg, cyclosporine, azathioprine) are then used instead. Immunosuppressants are continued indefinitely.
Rejection develops in most patients despite immunosuppressive therapy. Symptoms and signs are similar in hyperacute, acute, and chronic forms and include fever, dyspnea, cough, decreased SaO2 (arterial O2 saturation), and a decrease in FEV1 by > 10 to 15%.
Hyperacute rejection must be distinguished from early graft dysfunction caused by ischemic injury during the transplantation procedure, and acute rejection must be differentiated from infection. Interstitial infiltrate, seen on chest x-rays, is typical in patients with accelerated or acute rejection. Rejection is usually diagnosed by bronchoscopy, including bronchoscopic transbronchial biopsy. If rejection has occurred, biopsy shows perivascular lymphocytic infiltration in small vessels; polymorphonuclear leukocytes in alveolar infiltrates and infectious pathogens suggest infection. IV corticosteroids are usually effective for hyperacute, accelerated, or acute rejection. Treatment of recurrent or resistant cases varies and includes higher corticosteroid doses, aerosolized cyclosporine, ATG, and OKT3.
Chronic rejection develops after > 1 yr in up to 50% of patients; it manifests as obliterative bronchiolitis or, less commonly, as atherosclerosis. Acute rejection may increase risk of chronic rejection. Patients with obliterative bronchiolitis present with cough, dyspnea, and decreased FEF25-75% or FEV1, with or without physical and radiographic evidence of an airway process. Differential diagnosis includes pneumonia. Diagnosis is usually by bronchoscopy with biopsy. No treatment has proved effective, but options include corticosteroids, ATG or OKT3, inhaled cyclosporine, and retransplantation.
The most common surgical complications are poor healing of the bronchial or tracheal anastomosis (diagnosed when mediastinal air or pneumothorax is detected) and infection. Up to 20% of single-lung recipients develop bronchial stenosis that causes wheezing and airway obstruction; it can be treated with dilation or stent placement. Other surgical complications include hoarseness and diaphragmatic paralysis, caused by damage to the recurrent laryngeal or phrenic nerves; GI dysmotility, caused by damage to the thoracic vagus nerve; and pneumothorax. Supraventricular arrhythmias develop in some patients, probably because of conduction changes caused by pulmonary vein-atrial suturing.
Patient survival rates are
Mortality rate is higher for patients with primary pulmonary hypertension, idiopathic pulmonary fibrosis, or sarcoidosis and lower for those with COPD or α1-antitrypsin deficiency. Mortality rate is higher for single lung transplantation than for double.
Most common causes of death are
Mortality risk factors include cytomegalovirus mismatching (donor positive, recipient negative), human leukocyte antigen (HLA-DR) mismatching, diabetes, and prior need for mechanical ventilation or inotropic support.]]
Uncommonly, the original disorder, particularly some interstitial lung disorders, recurs. Exercise capacity is slightly limited because of a hyperventilatory response.
With heart-lung transplantation, overall survival rate at 1 yr is 60% for patients and grafts.
Last full review/revision April 2013 by Martin Hertl, MD, PhD; Paul S. Russell, MD